TaiMed Biologics Inc. (TPEX:4147)

Market Cap	20.76B
Revenue (ttm)	607.46M
Net Income (ttm)	-211.60M
Shares Out	273.12M
EPS (ttm)	-0.77
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,423,249
Average Volume	448,504
Open	82.20
Previous Close	76.00
Day's Range	77.40 - 82.80
52-Week Range	65.90 - 108.50
Beta	-0.06
RSI	55.72
Earnings Date	May 13, 2025

About TaiMed Biologics

TaiMed Biologics Inc., a biotechnology company, develops, manufactures, and commercializes drugs for the treatment and prevention of infectious diseases. It develops and markets Trogarzo IV infusion and Trogarzo IV push, a monoclonal antibody for HIV treatment. The company is also developing TMB-365, a monoclonal antibody used for HIV treatment and prevention which has completed a phase-1 clinical trial; and TMB-365 and TMB-380 combination, a monoclonal antibody combination therapy for HIV that is in phase-1b/2a clinical trial, as well as antib...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2007
• Country: Taiwan
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 4147

Financial Performance

In 2024, TaiMed Biologics's revenue was 610.16 million, an increase of 24.07% compared to the previous year's 491.78 million. Losses were -201.83 million, 3.60% more than in 2023.